Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI)
$0.40
-0.0200 ( -4.80% ) 75.9K
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Market Data
Open
$0.40
Previous close
$0.42
Volume
75.9K
Market cap
$32.18M
Day range
$0.40 - $0.43
52 week range
$0.13 - $1.95
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-k | Annual reports | 84 | Apr 01, 2024 |
8-k | 8K-related | 15 | Apr 01, 2024 |
4 | Insider transactions | 1 | Mar 13, 2024 |
4 | Insider transactions | 1 | Mar 13, 2024 |
4 | Insider transactions | 1 | Mar 13, 2024 |
4 | Insider transactions | 1 | Mar 13, 2024 |
8-k | 8K-related | 13 | Dec 20, 2023 |
8-k | 8K-related | 13 | Nov 22, 2023 |
10-q | Quarterly Reports | 53 | Nov 14, 2023 |
8-k | 8K-related | 13 | Nov 14, 2023 |